ARYX Projected Dividend Yield

Aryx Therapeutics Inc ( OTCBB : ARYX )

ARYx Therapeutics is a biopharmaceutical company engaged in developing a portfolio of product candidates designed to eliminate known safety issues associated with drugs. As of Dec 31 2009, Co.'s product candidates include Tecarfarin ATI-5923, an oral anticoagulant to prevent the formation of blood clots; Budiodarone ATI-2042, an oral antiarrhythmic for the treatment of atrial fibrillation; ATI-7505, an oral prokinetic for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent for the treatment of schizophrenia and other psychiatric disorders.

20 YEAR PERFORMANCE RESULTS